KIT and gastrointestinal stromal tumor: The treatment of c-Kit mutant GIST with imatinib mesylate, a selective inhibitor targeting c-Kit, Abl and platelet-derived growth factor receptor, produces responses in 80% of patients with over 90% of these patients remaining progression free at one year [4].